A Registry to Track Scleroderma Progression


About this study

The purpose of this study is to to develop an early systemic sclerosis ((SSc), scleroderma defined as < 5 years from 1st non- Raynaud’s Phenomenon (RP) symptom attributable to SSc) observational cohort in the United States (US).


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients 18 and older, inclusive; AND
  • Patients who meet the 2013 ACR/EULAR classification criteria for systemic sclerosis; AND
  • < 5 years from onset of first non-RP symptom attributed to systemic sclerosis.

Exclusion Criteria:

  • Patients under 18 years of age.
  • Patients with cognitive impairment that will interfere with conducting the study. Study staff should determine if the patient, at that moment, has the cognitive capacity to understand what the study entails, assent to participate, and complete the assessments. If there is question as to whether a patient may meet this criterion, RCs/RAs should defer to the site PI trained on the study to help determine; OR
  • Patients who are non-English Speaking. The patient must be able to proficiently read, speak, and understand English in order to be eligible.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ashima Makol, M.B.B.S.

Open for enrollment

Contact information:

Jennifer Sletten

(507) 284-3695


More information


Publications are currently not available

Mayo Clinic Footer